Overexpression of aldo-keto reductase 1C2 as a high-risk factor in bladder cancer

Oncology Reports

Volumn 17, Issue 2, 2007, Pages 305-311

  Tai, Hui Lung ^a,b   Lin, Torng Sen ^a,b   Huang, Hsuan Hua ^c   Lin, Tze Yi ^d   Chou, Ming Chih ^b   Chiou, Shiow Her ^e   Chow, Kuan Chih ^e  

^a CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^c FENG YUAN HOSPITAL   (Taiwan)

^d Hsin Chu General Hospital   (Taiwan)

^e NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

Author keywords

Aldo keto reductase 1C2; Black foot disease; Transitional cell carcinoma; Urinary bladder cancer

Indexed keywords

AKR1C2 PROTEIN, HUMAN; ARSENIC; HYDROXYSTEROID DEHYDROGENASE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BIOSYNTHESIS; BLADDER TUMOR; DISEASE COURSE; DNA SEQUENCE; DRUG RESISTANCE; ENZYMOLOGY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MASS SPECTROMETRY; MIDDLE AGED; PATHOLOGY; PHENOTYPE; RISK; TRANSITIONAL CELL CARCINOMA;

ADULT; ARSENIC; CARCINOMA, TRANSITIONAL CELL; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; HYDROXYSTEROID DEHYDROGENASES; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PHENOTYPE; RISK; SEQUENCE ANALYSIS, DNA; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; URINARY BLADDER NEOPLASMS;

EID: 33947713276     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.17.2.305     Document Type: Article

References (43)

1. Annual Reports of the Department of Health, the Executive Yuan, Republic of China, 2003.
2. Chen CJ, Chuang YC, You SL, Lin TM and Wu HY: A retrospective study on malignant neoplasms of bladder, lung and liver in blackfoot disease endemic area in Taiwan. Br J Cancer 53: 399-405, 1986.
3. Chiang HS, Guo HR, Hong CL, Lin SM and Lee EF: The incidence of bladder cancer in the black foot disease endemic area in Taiwan. Br J Urol 71: 274-278, 1993. (Pubitemid 23102250)
4. Tseng WP, Chu HM, How SW, Fong JM, Lin CS and Yeh S: Prevalence of skin cancer in an endemic area of chronic arsenicism in Taiwan. J Natl Cancer Inst 40: 453-463, 1968.
5. Chen YC, Guo YL, Su HJ, et al: Arsenic methylation and skin cancer risk in southwestern Taiwan. J Occup Environ Med 45: 241-248, 2003.
6. Ko YC: A critical review of epidemiologic studies on black-foot disease. J UOEH 8: 339-353, 1986.
7. Kuo T: Arsenic content of artesian well water in endemic area of chronic arsenic poisoning. Rep Inst Pathol Natl Taiwan Univ 20: 7-13, 1968.
8. Gomez-Caminero A, Howe P, Hughes M, et al: Arsenic and arsenic compounds. In: Environmental Health Criteria 224. Ng J (coordinator). United Nations Environment Programme, the International Labour Organization, and the World Health Organization, Geneva, www.inchem.org/documents/ehc/ehc/ehc224.htm, 2001.
9. Fukushima S and Wanibuchi H: Prevention of urinary bladder cancer: the interface between experimental and human studies. Asian Pac J Cancer Prev 1: 15-33, 2000.
10. Shibata A, Ohneseit PF, Tsai YC, et al: Mutational spectrum in the p53 gene in bladder tumors from the endemic area of black foot disease in Taiwan. Carcinogenesis 15: 1085-1087, 1994. (Pubitemid 24193869)
11. Moch H, Sauter G, Mihatsch MJ, Gudat F, Epper R and Waldman FM: p53 but not erbB-2 expression is associated with rapid tumor proliferation in urinary bladder cancer. Hum Pathol 25: 1346-1351, 1994. (Pubitemid 24378743)
12. Skopelitou A, Hadjiyannakis M, Dimopoulos D, et al: p53 and c-jun expression in urinary bladder transitional cell carcinoma: correlation with proliferating cell nuclear antigen (PCNA) histological grade and clinical stage. Eur Urol 31: 464-471, 1997. (Pubitemid 27234639)
13. Ecke TH, Lenk SV, Schlechte HH and Loening SA: Tissue polypeptide antigen (TPA) in comparison with mutations of tumour suppressor gene P53 (TP53) in patients with bladder cancer. Anticancer Res 23: 957-962, 2003. (Pubitemid 36750902)
14. Knapp DW, Richardson RC, Chan TC, et al: Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder. J Vet Intern Med 8: 273-278, 1994.
15. Wang LS, Chow KC and Wu YC: Effects of platelet activating factor, butyrate and interleukin-6 on cyclooxygenase-2 expression in human esophageal cancer cells. Scand J Gastroenterol 37: 467-475, 2002.
16. Kuo KT, Chow KC, Wu YC, et al: Clinicopathologic significance of cyclooxygenase-2 overexpression in esophageal squamous cell carcinoma. Ann Thorac Surg 76: 909-914, 2003.
17. Matsuura K, Shiraishi H, Hara A, et al: Identification of a principal mRNA species for human 3alpha-hydroxysteroid dehydrogenase isoform (AKR1C3) that exhibits high prostaglandin D2 11-ketoreductase activity. J Biochem 124: 940-946, 1998. (Pubitemid 28544904)
18. Hsu NY, Ho HC, Chow KC, et al: Overexpression of dihydrodiol dehydrogenase as a prognostic marker of non-small cell lung cancer. Cancer Res 61: 2727-2731, 2001.
19. Vogel K, Bentley P, Platt KL and Oesch F: Rat liver cytoplasmic dihydrodiol dehydrogenase. J Biol Chem 255: 9621-9625, 1980.
20. Cheng KC: Molecular cloning of rat liver 3 α-hydroxysteroid dehydrogenase and related enzymes from rat liver, kidney and lung. J Steroid Biochem Mol Biol 43: 1083-1088, 1992.
21. Watanabe K, Fujii Y, Nakayama K, et al: Structural similarity of bovine lung prostaglandin F synthase to lens epsilon-crystallin of the European common frog. Proc Natl Acad Sci USA 85: 11-15, 1988.
22. Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG and Morrow M (eds): Urinary bladder. American Joint Committee on Cancer. In: AJCC Cancer Staging Manual. 6th edition. Springer, New York, pp335-340, 2002.
23. Remmele W and Schicketanz KH: Immunohistochemical determination of estrogen and progesterone receptor content in human breast cancer. Computer-assisted image analysis (QIC score) vs. subjective grading (IRS). Pathol Res Pract 189: 862-866, 1993. (Pubitemid 23308006)
24. Wang LS, Chow KC, Wu YC, Hsu NY and Lin TY: Inverse expressions of dihydrodiol dehydrogenase and glutathione-Stransferase in patients with esophageal squamous cell carcinoma. Int J Cancer 111: 246-251, 2004.
25. Chen YJ, Yuan CC, Chow KC, et al: Overexpression of dihydrodiol dehydrogenase is associated with cisplatin-based chemotherapy resistance in ovarian cancer patients. Gynecol Oncol 97: 110-117, 2005.
26. Liu SX, Davidson MM, Tang X, et al: Mitochondrial damage mediates genotoxicity of arsenic in mammalian cells. Cancer Res 65: 3236-3242, 2005. (Pubitemid 40524606)
27. Wei M, Wanibuchi H, Morimura K, et al: Carcinogenicity of dimethylarsinic acid in male F344 rats and genetic alterations in induced urinary bladder tumors. Carcinogenesis 23: 1387-1397, 2002.
28. Ochi T: Arsenic compound-induced increases in glutathione levels in cultured Chinese hamster V79 cells and mechanisms associated with changes in gamma-glutamylcysteine synthetase activity, cystine uptake and utilization of cysteine. Arch Toxicol 71: 730-740, 1997.
29. Simeonova PP, Wang S, Toriuma W, et al: Arsenic mediates cell proliferation and gene expression in the bladder epithelium: association with activating protein-1 transactivation. Cancer Res 60: 3445-3453, 2000. (Pubitemid 30482163)
30. Liu L, Trimarchi JR, Navarro P, Blasco MA and Keefe DL: Oxidative stress contributes to arsenic-induced telomere attrition, chromosome instability, and apoptosis. J Biol Chem 278: 31998-32004, 2003. (Pubitemid 37051543)
31. Naito S, Kotoh S, Omoto T, et al: Prophylactic intravesical instillation chemotherapy against recurrence after a transurethral resection of superficial bladder cancer: a randomized controlled trial of doxorubicin plus verapamil versus doxorubicin alone. The Kyushu University Urological Oncology Group. Cancer Chemother Pharmacol 42: 367-372, 1998. (Pubitemid 28430366)
32. Nomata K, Noguchi M, Kanetake H, et al: Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of a randomized trial with epirubicin comparing short-term versus long-term maintenance treatment. Cancer Chemother Pharmacol 50: 266-270, 2002.
33. Pectasides D, Pectasides M and Nikolaou M: Adjuvant and neoadjuvant chemotherapy in muscle invasive bladder cancer: literature review. Eur Urol 48: 60-67, 2005. (Pubitemid 40835592)
34. Nieuwenhuijzen JA, Bex A, Meinhardt W, et al: Neoadjuvant methotrexate, vinblastine, doxorubicin and cisplatin for histologically proven lymph node positive bladder cancer. J Urol 174: 80-85, 2005.
35. Ax W, Soldan M, Koch L and Maser E: Development of daunorubicin resistance in tumour cells by induction of carbonyl reduction. Biochem Pharmacol 59: 293-300, 2000. (Pubitemid 30001756)
36. Shen H, Kauvar L and Tew KD: Importance of glutathione and associated enzymes in drug response. Oncol Res 9: 295-302, 1997. (Pubitemid 127825983)
37. Deng HB, Parekh HK, Chow KC and Simpkins H: Increased expression of dihydrodiol dehydrogenase induces resistance to cisplatin in human ovarian carcinoma cells. J Biol Chem 277: 15035-15043, 2002. (Pubitemid 34952580)
38. Kioka N, Hosokawa N, Komano T, Hirayoshi K, Nagata K and Ueda K: Quercetin, a bioflavonoid, inhibits the increase of human multidrug resistance gene (MDR1) expression caused by arsenite. FEBS Lett 301: 307-309, 1992.
39. Prestera T, Holtzclaw WD, Zhang Y and Talalay P: Chemical and molecular regulation of enzymes that detoxify carcinogens. Proc Natl Acad Sci USA 90: 2965-2969, 1993. (Pubitemid 23113538)
40. Ramos AM, Fernandez C, Amran D, Sancho P, De Blas E and Aller P: Pharmacologic inhibitors of PI3K/Akt potentiate the apoptotic action of the antileukemic drug arsenic trioxide via glutathione depletion and increased peroxide accumulation in myeloid leukemia cells. Blood 105: 4013-4020, 2005. (Pubitemid 40656150)
41. Nutt LK, Gogvadze V, Uthaisang W, Mirnikjoo B, McConkey DJ and Orrenius S: Indirect effects of Bax and Bak initiate the mitochondrial alterations that lead to cytochrome c release during arsenic trioxide-induced apoptosis. Cancer Biol Ther 4: 459-467, 2005. (Pubitemid 41351266)
42. Chow KC, Lu MP and Wu MT: Expression of dihydrodiol dehydrogenase plays important roles in apoptosis- and drugresistance of A431 squamous cell carcinoma. J Dermatol Sci 41: 205-212, 2005.
43. Ueda M, Hung YC, Chen JT, et al: Infection of human papillomavirus and overexpression of dihydrodiol dehydrogenase in uterine cervical cancer. Gynecol Oncol 102: 173-181, 2006. (Pubitemid 44041634)